FDA Accelerates Approval of Generic Biologics to Cut Drug Costs
TL;DR
The FDA announced new measures to streamline the development and approval of biosimilar drugs, aiming to lower costs and increase access to affordable biologic treatments by simplifying testing requirements and promoting interchangeability, thereby fostering market competition and reducing healthcare expenses.
- FDA Moves to Accelerate Biosimilar Development and Lower Drug Costs fda.gov
- F.D.A. Moves to Speed Approvals for Cheaper Copycat Drugs The New York Times
- HHS Sec. Robert F. Kennedy & FDA Commissioner Marty Makary on Drug Prices C-SPAN
- FDA to speed up approvals of generic biologic medicines as Trump targets high drug costs CNBC
- FDA to streamline approvals for generic biological drugs in latest move targeting health costs CNN
Want the full story? Read the original reporting
Read on fda.gov